Search
for
Sort by
Research 61–90 of 1000+
- First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study
- Real-World Safety Profile of Generic Palbociclib in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Prospective Observational Study in Iraq”
- The Breast Cancer Wars: Fear, Hope and the Pursuit of a Cure in Twentieth Century America
- Aromatase inhibitor therapy and hair loss among breast cancer survivors
- Relationship of Early-Onset Baldness to Prostate Cancer in African-American Men
- Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer
- Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies
- The Black identity, hair product use, and breast cancer scale
- Efficacy of Scalp Cooling combined with DHL-HisZnNa Lotion in the Prevention of Chemotherapy-Induced Alopecia in Patients with Breast Cancer
- Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents
- Endocrine correlates of male breast cancer risk: a case-control study in Athens, Greece
- Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients
- Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer
- Persistent Alopecia in a Breast Cancer Patient Following Taxane Chemotherapy and Adjuvant Endocrine Therapy: Case Report and Review of Post-treatment Hair Loss in Oncology Patients with Breast Cancer
- ANALYSIS OF ADVERSE DRUG REACTIONS (ADRs) AND THEIR SEVERITY IN BREAST CANCER PATIENTS TREATED WITH THE DOCETAXEL-DOXORUBICIN REGIMEN AT SULTAN AGUNG ISLAMIC HOSPITAL
- Prevalence and Partern of Early Adverse Reactions in Cancer Patients Receiving Chemotherapy at Ocean Road Cancer Institute
- The evolution of primary multimodality treatment in resectable breast cancer
- Scalp cooling has no place in the prevention of alopecia in adjuvant chemotherapy for breast cancer
- Alopecia induced by CDK 4/6 Inhibitors and its Impact on the Quality of Life of Patients with advanced Breast cancer
- Formestane Preferred as Second-Line Therapy in Advanced Breast Cancer
- Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis
- Scalp hypothermia for the prevention of chemotherapy-induced alopecia in breast cancer
- Efficacy of Scalp Cooling in the Prevention of Chemotherapy Induced Alopecia Among Breast Cancer Patients
- Fibroblast heterogeneity and functions: insights from single-cell sequencing in wound healing, breast cancer, ovarian cancer and melanoma
- Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
- Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody–drug conjugate in breast cancer
- A discrete transition zone between cuticle and cortex layers of a human hair fibre: changes observed in the presence of breast cancer
- Diagnosis of breast cancer by X-ray diffraction of hair
- Survey on adverse events associated with drug therapy for breast cancer patients
- Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer